Oruka Therapeutics, Inc. (ORKA)
| Market Cap | 7.15B +423.7% |
| Revenue (ttm) | n/a |
| Net Income | -130.37M |
| EPS | -2.13 |
| Shares Out | 67.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 679,676 |
| Open | 104.28 |
| Previous Close | 104.99 |
| Day's Range | 101.56 - 106.87 |
| 52-Week Range | 25.23 - 115.52 |
| Beta | -0.17 |
| Analysts | Strong Buy |
| Price Target | 156.17 (+48.24%) |
| Earnings Date | Nov 9, 2026 |
About ORKA
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ORKA stock is "Strong Buy." The 12-month stock price target is $156.17, which is an increase of 48.24% from the latest price.
News
Oruka Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
Two independent ORKA-001 studies showed low-60% PASI 100 at 600 mg, with week 52 maintenance data expected in December. Phase III is targeted for the first half of next year; ORKA-002 psoriasis data are planned for Q1 next year.
Oruka Therapeutics reports Q3 EPS (63c), consensus (62c)
“We continued to make rapid progress in the third quarter and shared two new datasets from the EVERLAST program with ORKA-001 that further strengthen our belief that it can set…
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A
Oruka Therapeutics Quarterly report: Q3 2026
Oruka Therapeutics has published its Q3 2026 quarterly earnings report on November 9, 2026.
Oruka Therapeutics Earnings release: Q3 2026
Oruka Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standar...
Oruka Therapeutics price target lowered to $105 from $131 at Clear Street
Clear Street analyst Kaveri Pohlman lowered the firm’s price target on Oruka Therapeutics (ORKA) to $105 from $131 and keeps a Buy rating on the shares. The firm notes the…
Oruka Therapeutics rises 14.3%
Oruka Therapeutics (ORKA) is up 14.3%, or $11.47 to $91.62.
Oruka Therapeutics rises 11.6%
Oruka Therapeutics (ORKA) is up 11.6%, or $9.29 to $89.44.
Oruka Therapeutics Transcript: Study result
ORKA-001 achieved 61% PASI 100 and 86% PASI 90 at week 16 with 600 mg, consistent with EVERLAST-A; pooled across both studies, PASI 100 was ~63%. The 600 mg regimen is planned for phase III in H1 2027, pending regulatory discussions.
Oruka Therapeutics Press release: Study result
Oruka Therapeutics issued a press release on October 26, 2026, disclosing material business information to investors.
Oruka Therapeutics Slides: Study result
Oruka Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
Oruka Therapeutics announces results from EVERLAST trial of ORKA-001
Oruka Therapeutics (ORKA) announced Week 16 results from its EVERLAST-B Phase 2b trial of ORKA-001, a half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe PsO. Efficacy increased in ...
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on t...
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standar...
Oruka Therapeutics ORKA-001 data meet base case, says Clear Street
Clear Street says Oruka Therapeutics (ORKA)’ ORKA-001 update today met its base case. PASI 100 increased to 71.4% at week 28 from the “class-leading” 63.5% rate at week 16 despite…
Oruka Therapeutics announces Week 28 results for ORKA-001
Oruka Therapeutics (ORKA) announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psori...
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ...
Oruka Therapeutics Slides: Corporate presentation
Oruka Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 23, 2026.
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standa...
Oruka Therapeutics appoints Todd Edwards as chief commercial officer
Oruka Therapeutics (ORKA) announced the appointment of Todd Edwards as chief commercial officer, effective August 24. Edwards joins Oruka from Arcutis Biotherapeutics (ARQT), where he served as execut...
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standar...
Oruka Therapeutics files $1B mixed securities shelf
16:20 EDT Oruka Therapeutics (ORKA) files $1B mixed securities shelf
Oruka Therapeutics Registration statement: Registration filing
Oruka Therapeutics filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
Oruka Therapeutics reports Q2 EPS (55c), consensus (50c)
“The second quarter and recent months were highly productive as we advanced both of our co-lead programs toward a series of important readouts,” said Lawrence Klein, Chief Executive Officer of…